Chemed (CHE) Expected to Announce Earnings on Wednesday

Chemed (NYSE:CHE - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, July 23rd. Analysts expect the company to announce earnings of $6.02 per share and revenue of $650.60 million for the quarter.

Chemed (NYSE:CHE - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The company reported $5.63 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.04. Chemed had a return on equity of 27.58% and a net margin of 12.40%. The business had revenue of $646.94 million during the quarter, compared to the consensus estimate of $641.78 million. During the same period in the prior year, the company posted $5.20 EPS. The business's quarterly revenue was up 9.8% on a year-over-year basis. On average, analysts expect Chemed to post $21 EPS for the current fiscal year and $23 EPS for the next fiscal year.

Chemed Stock Performance

Shares of CHE traded down $0.72 during trading hours on Thursday, hitting $456.58. 52,639 shares of the stock were exchanged, compared to its average volume of 111,961. Chemed has a 12-month low of $452.05 and a 12-month high of $623.61. The company has a market cap of $6.68 billion, a price-to-earnings ratio of 22.26, a price-to-earnings-growth ratio of 2.18 and a beta of 0.50. The stock's 50-day moving average price is $537.60 and its two-hundred day moving average price is $559.38.

Chemed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 17th. Shareholders of record on Thursday, May 29th were paid a $0.50 dividend. The ex-dividend date of this dividend was Thursday, May 29th. This represents a $2.00 annualized dividend and a dividend yield of 0.44%. Chemed's dividend payout ratio (DPR) is currently 9.74%.

Analysts Set New Price Targets

CHE has been the topic of several recent analyst reports. Wall Street Zen cut Chemed from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. Bank of America lowered their target price on Chemed from $708.00 to $650.00 and set a "buy" rating for the company in a report on Monday, June 30th. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $640.00 price objective (down from $674.00) on shares of Chemed in a report on Monday, June 30th.

Insider Activity at Chemed

In other news, EVP Spencer S. Lee sold 1,500 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $577.99, for a total transaction of $866,985.00. Following the transaction, the executive vice president directly owned 14,627 shares of the company's stock, valued at approximately $8,454,259.73. This trade represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin J. Mcnamara sold 1,500 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $576.45, for a total transaction of $864,675.00. Following the transaction, the chief executive officer directly owned 101,197 shares in the company, valued at $58,335,010.65. This represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,500 shares of company stock worth $2,598,450 over the last three months. 3.29% of the stock is owned by company insiders.

Hedge Funds Weigh In On Chemed

An institutional investor recently raised its position in Chemed stock. Geneos Wealth Management Inc. lifted its holdings in shares of Chemed Corporation (NYSE:CHE - Free Report) by 330.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 99 shares of the company's stock after acquiring an additional 76 shares during the period. Geneos Wealth Management Inc.'s holdings in Chemed were worth $61,000 at the end of the most recent reporting period. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.